Immix Biopharma
IMMX
18 hedge funds and large institutions have $1.75M invested in Immix Biopharma in 2023 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
139% more capital invested
Capital invested by funds: $730K → $1.75M (+$1.02M)
50% more funds holding
Funds holding: 12 → 18 (+6)
1.48% more ownership
Funds ownership: 2.88% → 4.37% (+1.5%)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
+$419K |
| 2 |
Koshinski Asset Management
Decatur,
Illinois
|
+$107K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$47.8K |
| 4 |
IW
Imprint Wealth
Mount Pleasant,
South Carolina
|
+$46.7K |
| 5 |
BlackRock
New York
|
+$32.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UB
UMB Bank
Kansas City,
Missouri
|
-$55.8K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$40.6K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$32.3K |
| 4 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
-$19.5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$13.1K |
IMMX Hedge Fund Activity: Q2 2023 in Review
18 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q2 2023, worth a combined $1.75M — up 139% from $730K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new IMMX positions and 3 closed out — a net gain of 6 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Lynwood Capital Management, opening a new position worth an estimated $419K. The largest seller was UMB Bank, cutting an estimated $55.8K.
- 18 institutional investors held Immix Biopharma (IMMX) as of Q2 2023, up from 12 in Q1 2023.
- Funds reported $1.75M of Immix Biopharma stock for Q2 2023, up 139% quarter-over-quarter.
- 9 funds opened new Immix Biopharma positions in Q2 2023 and 3 closed out, a net change of +6 holders.
- The largest Immix Biopharma buyer in Q2 2023 was Lynwood Capital Management, an estimated $419K added.
- The largest Immix Biopharma seller in Q2 2023 was UMB Bank, an estimated $55.8K sold.
Based on aggregated 13F filings for Q2 2023.